GlassScriptPhysician profile
David S Ramin
NPI 1992893424
$13,882.83
in general payments reported to CMS, 2019-2025
49 companies · $2,837 in 2025
The $2,837 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,407 · 2020: $1,645 · 2021: $1,482 · 2022: $1,760 · 2023: $1,379 · 2024: $2,373 · 2025: $2,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,588.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,296.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,585.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,500.15 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Janssen Pharmaceuticals, INC | $1,110.49 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $733.99 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $712.16 | 2019-2025 | Trintellix |
| Pfizer INC. | $645.20 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.29 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $527.68 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $407.02 | 2019-2025 | |
| Gilead Sciences, INC. | $401.87 | 2019-2025 | Yeztugo |
| Glaxosmithkline, LLC. | $340.95 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.93 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $218.63 | 2019-2021 | |
| Boston Scientific Corporation | $202.77 | 2019-2025 | Artisan |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ramin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.